<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="49c998c7-d0b4-4527-8e34-dc5edc59a40f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use IWILFIN® safely and effectively. See full prescribing information for IWILFIN. <br/>
      <br/> IWILFIN® (eflornithine) tablets, for oral use 		<br/> Initial U.S. Approval: 2023</title>
   <effectiveTime value="20241213"/>
   <setId root="6716d8cc-66e6-4cee-935c-ccb85ed984f5"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="117542566" root="1.3.6.1.4.1.519.1"/>
            <name>USWM, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="657484726" root="1.3.6.1.4.1.519.1"/>
                        <name>ScinoPharm Taiwan Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="780516717" root="1.3.6.1.4.1.519.1"/>
                        <name>CoreRx Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="071344167" root="1.3.6.1.4.1.519.1"/>
                        <name>Quality Chemical Laboratories</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="118348161" root="1.3.6.1.4.1.519.1"/>
                        <name>Aphena Pharma Solutions - TN, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="808308303" root="1.3.6.1.4.1.519.1"/>
                        <name>SGS North America</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="072229d1-a570-452d-ac0e-116cf65bca88"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241130"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="78670-150" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>iwilfin</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>EFLORNITHINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator value="250" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4NH22NDW9H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EFLORNITHINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="ZQN1G5V6SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EFLORNITHINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="UO07O10TCJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EFLORNITHINE HYDROCHLORIDE ANHYDROUS</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>microcrystalline cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>silicon dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="78670-150-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240115"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215500" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">EFL;192</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="52fd6300-f36d-4f30-8013-b2327af38621"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.3">2.3</linkHtml>)</td>
                                 <td>11/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="7c301769-c8de-4169-8eab-cb89b2185934"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1	INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>IWILFIN is an ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="b0ea55ac-35fa-4813-9817-6e36ad1bb178"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2	DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Prior to initiation of IWILFIN, perform baseline audiogram, complete blood count, and liver function tests. (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Recommended dosage of IWILFIN is based on body surface area <content styleCode="italics">(see <linkHtml href="#table1">Table 1</linkHtml>).</content> (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>IWILFIN is taken orally twice daily with or without food until disease progression, unacceptable toxicity, or for a maximum of two years. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>IWILFIN tablets may be swallowed whole, chewed, or crushed and mixed with soft food or liquid. (<linkHtml href="#S2.5">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="420bdce9-bd09-45f7-af48-f0f584b4a50d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 	Recommended Testing Before Initiating IWILFIN</title>
                     <text>
                        <paragraph>Prior to initiating IWILFIN, perform complete blood count, liver function tests, and baseline audiogram <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>-<linkHtml href="#S5.3">5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="0d27debc-83bb-447a-bd74-99168b8f26aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	 Recommended Dosage of IWILFIN</title>
                     <text>
                        <paragraph>The recommended IWILFIN dosage, based on body surface area (BSA), is provided in Table 1.</paragraph>
                        <paragraph>Administer IWILFIN orally twice daily for two years or until recurrence of disease or unacceptable toxicity.</paragraph>
                        <paragraph>Recalculate the BSA dosage every 3 months during treatment with IWILFIN.</paragraph>
                        <table width="75%" ID="table1">
                           <caption>Table 1: Recommended Dose</caption>
                           <col width="40%" align="left" valign="top"/>
                           <col width="60%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Body Surface Area (m<sup>2</sup>)</th>
                                 <th styleCode="Rrule">Dosage</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">&gt;1.5</td>
                                 <td styleCode="Rrule">768 mg (four tablets) orally twice a day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.75 to 1.5</td>
                                 <td styleCode="Rrule">576 mg (three tablets) orally twice a day </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.5 to &lt; 0.75</td>
                                 <td styleCode="Rrule">384 mg (two tablets) orally twice a day </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">0.25 to &lt; 0.5</td>
                                 <td styleCode="Rrule">192 mg (one tablet) orally twice a day </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="08c22da4-575e-4a13-a0e7-ddfd9e9a5f5f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Recommendations for Renal Impairment</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">For the treatment of patients with severe renal impairment (eGFR &lt;30 mL/min), reduce the recommended dose of IWILFIN by 50% as described in Table 2 [<content styleCode="italics">see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                              </content>].</content>
                        </paragraph>
                        <table width="75%" ID="Table2">
                           <caption>Table 2:	 IWILFIN Dose Recommendations for Severely Renally Impaired Patients </caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="70%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Body Surface Area (m<sup>2</sup>)</th>
                                 <th styleCode="Rrule">Recommended Dosage for Patients with Severe Renal Impairment (eGFR &lt;30 mL/min)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">&gt;1.5</td>
                                 <td styleCode="Rrule">384 mg (two tablets) orally twice a day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.75 to 1.5</td>
                                 <td styleCode="Rrule">384 mg (two tablets) in the morning and 192 mg (one tablet) in the evening</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.5 to &lt; 0.75</td>
                                 <td styleCode="Rrule">192 mg (one tablet) orally twice a day</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">0.25 to &lt; 0.5</td>
                                 <td styleCode="Rrule">192 mg (one tablet) once a day</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="aa9e70b0-6e2e-4b03-923a-23dd22173f2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>The recommended dose reductions for adverse reactions are provided in Table 3. </paragraph>
                        <table width="75%">
                           <caption>Table 3:	 Recommended IWILFIN Dose Reductions for Toxicity Management</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Current Dose</th>
                                 <th styleCode="Rrule">Reduced Dose</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">768 mg (four tablets) orally twice a day</td>
                                 <td styleCode="Rrule">576 mg (three tablets) orally twice a day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">576 mg (three tablets) orally twice a day</td>
                                 <td styleCode="Rrule">384 mg (two tablets) orally twice a day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">384 mg (two tablets) orally twice a day</td>
                                 <td styleCode="Rrule">192 mg (one tablet) orally twice a day</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">192 mg (one tablet) orally twice a day</td>
                                 <td styleCode="Rrule">192 mg (one tablet) orally once daily</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>If subsequent adverse reactions occur, continue dose reduction until reaching the minimum dose of one 192 mg tablet once per day. Permanently discontinue IWILFIN if the patient is unable to tolerate the minimum dose of 192 mg once daily.</paragraph>
                        <paragraph>The recommended dosage modifications of IWILFIN for the management of adverse reactions are provided in Table 4. </paragraph>
                        <table width="80%">
                           <caption>Table 4:	Recommended IWILFIN Dosage Modifications for Adverse Reactions</caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="30%" align="left" valign="top"/>
                           <col width="40%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                 <th styleCode="Rrule">Severity<footnote ID="t3ft1">Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03</footnote>
                                 </th>
                                 <th styleCode="Rrule">Dosage Modification</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">Myelosuppression <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Neutrophil count decreased</td>
                                 <td styleCode="Rrule">&lt;500/mm<sup>3</sup>
                                 </td>
                                 <td styleCode="Rrule">Withhold IWILFIN until recovery to ≥500/mm<sup>3</sup>.<list listType="unordered" styleCode="disc">
                                       <item>If recovered within 7 days, resume IWILFIN at the same dose.</item>
                                       <item>If recovered after 7 days, resume IWILFIN at the next reduced dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Platelet count decreased</td>
                                 <td styleCode="Rrule">&lt;25,000/mm<sup>3</sup>
                                 </td>
                                 <td styleCode="Rrule">Withhold IWILFIN until recovery to ≥25,000/mm<sup>3</sup>.<list listType="unordered" styleCode="disc">
                                       <item>If recovered within 7 days, resume IWILFIN at the same dose.</item>
                                       <item>If recovered between 7 and 14 days, resume IWILFIN at the next reduced dose level.</item>
                                    </list>If not recovered within 14 days, permanently discontinue IWILFIN.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Anemia</td>
                                 <td styleCode="Rrule">&lt;8g/dL</td>
                                 <td styleCode="Rrule">Withhold IWILFIN until recovery to ≥8g/dL.<list listType="unordered" styleCode="disc">
                                       <item>Resume IWILFIN at the same dose.</item>
                                    </list>If anemia recurs (&lt;8g/dL)<list listType="unordered" styleCode="disc">
                                       <item>Withhold IWILFIN until recovery to ≥8g/dL.</item>
                                       <item>Resume IWILFIN at the next reduced dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Aspartate aminotransferase increased<br/>or<br/>Alanine aminotransferase increased</td>
                                 <td styleCode="Rrule">AST or ALT ≥10 × ULN </td>
                                 <td styleCode="Rrule">Withhold IWILFIN until recovery to &lt;10 × ULN.<list listType="unordered" styleCode="disc">
                                       <item>If recovered within 7 days, resume IWILFIN at the same dose.</item>
                                       <item>If recovered after 7 days, resume IWILFIN at the next reduced dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="italics">Hearing Loss [see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hearing loss</td>
                                 <td styleCode="Rrule">Clinically concerning new or worsening hearing loss compared to IWILFIN baseline audiogram</td>
                                 <td styleCode="Rrule">Continue dosing with IWILFIN and repeat audiogram in 3 weeks.<list listType="unordered" styleCode="disc">
                                       <item>If improved, continue IWILFIN at the same dose.</item>
                                       <item>If clinically concerning changes persist, hold IWILFIN for up to 30 days and repeat audiogram.</item>
                                    </list>If stable or improved, resume IWILFIN at the next reduced dose level.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">Other Adverse Reactions <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nausea, vomiting, or diarrhea</td>
                                 <td styleCode="Rrule">Grade 3</td>
                                 <td styleCode="Rrule">If symptoms respond to supportive treatment (e.g., anti-emetic, anti-diarrheal), continue dosing with IWILFIN at the same dose.<br/>If symptoms do not respond to treatment,<list listType="unordered" styleCode="disc">
                                       <item>Withhold IWILFIN until recovery to ≤ Grade 2.</item>
                                       <item>Resume IWILFIN at the next reduced dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Other adverse reactions</td>
                                 <td styleCode="Rrule">Grade 3 or 4</td>
                                 <td styleCode="Rrule">Withhold IWILFIN until recovery to ≤ Grade 2.<list listType="unordered" styleCode="disc">
                                       <item>Resume IWILFIN at the next reduced dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule">Recurrent Grade 4</td>
                                 <td styleCode="Rrule">Permanently discontinue IWILFIN.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="6f08bf9c-4d83-4bf6-8716-a0d379d1e8d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Administration, Crushed Preparation, and Missed Dose Instructions</title>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section>
                           <id root="40f8bdc4-b824-460c-9a56-15e3e180f5b7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Administration</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Administer IWILFIN orally twice daily, with or without food, for two years or until recurrence of disease or unacceptable toxicity <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</item>
                                 <item>IWILFIN tablets can be swallowed whole, chewed, or crushed.</item>
                              </list>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="166dde15-c905-4726-8432-32c935109f2a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Crushed Preparation</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>For patients who have difficulty swallowing tablets, IWILFIN can be chewed, or crushed then mixed with two tablespoons of soft food or liquid.</item>
                                 <item>Visually confirm the entire contents are consumed. If any crushed tablet particles remain in the container, mix with an additional small volume (e.g., no more than one ounce, 30 mL) of soft food or liquid.</item>
                                 <item>Discard crushed tablet preparation after one hour.</item>
                              </list>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ac1b1eb5-99b4-4a1e-918a-7d4847770e43"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Missed Dose</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>A missed dose of IWILFIN should be administered as soon as possible. If the next dose is due within 7 hours, the missed dose should be skipped.</item>
                                 <item>If vomiting occurs after taking IWILFIN, an additional dose should not be administered. Continue with the next scheduled dose.</item>
                              </list>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="366a5634-4161-4031-894e-3e87e8516ed6"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets: 192 mg eflornithine, white to off-white, round, imprinted with "EFL" on one side and "192" on the other side.</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 192 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="cd646f95-45ce-4ee7-b250-b588bd2fadf8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4	CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="5a5e263d-7bc9-48e6-988b-a89404d3dbcf"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5	WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Myelosuppression:</content> Monitor blood counts before and during treatment with IWILFIN. Withhold, reduce dose, or permanently discontinue based on severity. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity:</content> Monitor liver function tests before and during treatment with IWILFIN. Withhold, reduce dose, or permanently discontinue based on severity. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hearing Loss:</content> Monitor hearing before and during treatment with IWILFIN. Withhold, reduce dose, or permanently discontinue based on severity. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity:</content> Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="0b6614e7-c181-4014-ae18-b546330a8339"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Myelosuppression</title>
                     <text>
                        <paragraph>IWILFIN can cause myelosuppression. In the pooled safety population <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>],</content> Grade 3 or 4 neutropenia occurred in 4.2% of patients. Febrile neutropenia occurred in 0.6% of patients. Bone marrow failure occurred in 1 patient. Grade 3 or 4 thrombocytopenia occurred in 1.4% of patients. Grade 3 anemia occurred in 3.3% of patients.</paragraph>
                        <paragraph>Monitor blood counts including neutrophil count, platelet count, and hemoglobin level prior to administration of IWILFIN and periodically during treatment. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="60b5bacb-a0d3-4dd9-917e-508d32ea4069"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hepatotoxicity</title>
                     <text>
                        <paragraph>IWILFIN can cause hepatotoxicity. In the pooled safety population <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>, Grade 3 or 4 events of increased alanine aminotransferase (ALT) occurred in 11% of patients. Grade 3 or 4 events of increased aspartate aminotransferase (AST) occurred in 6% of patients. Grade 3 or 4 events of increased bilirubin occurred in 0.3% of patients. Increased ALT/AST leading to dose interruption or reduction occurred in 2.5% of patients. IWILFIN was discontinued due to increased ALT/AST in 0.6% of patients. </paragraph>
                        <paragraph>Perform liver function tests (ALT, AST, and total bilirubin) prior to the start of IWILFIN, every month for the first six months of treatment, then once every 3 months or as clinically indicated, with more frequent testing in patients who develop transaminase or bilirubin elevations. Withhold and reduce the dose or permanently discontinue IWILFIN based on severity <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="3676b8a6-6a22-409d-84a3-8a7c48e36e65"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hearing Loss</title>
                     <text>
                        <paragraph>IWILFIN can cause hearing loss. In the pooled safety population <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>, 81% of patients had an abnormal audiogram at baseline. New or worsening hearing loss occurred in 13% of patients who received IWILFIN; hearing loss worsened from baseline to Grade 3 or 4 in 12% of patients. Tinnitus occurred in 1 patient. Hearing loss leading to dose interruption or reduction occurred in 4% of patients. New or worsening hearing loss requiring new use of hearing aids occurred in 7% of patients. IWILFIN was discontinued due to hearing loss in 1.4% of patients. Among all patients with new or worsening hearing loss during IWILFIN treatment, the hearing loss resolved to baseline in 9% of patients. Among 18 patients who experienced new or worsening hearing loss and had dose modifications, 67% (N=12) improved or resolved to baseline.</paragraph>
                        <paragraph>Perform audiogram prior to initiation of therapy and at 6 month intervals, or as clinically indicated, to monitor for potential hearing loss. Withhold and reduce the dose or permanently discontinue IWILFIN based on severity <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.4">2.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="4194a3b0-058e-4f4a-8e6f-06b5dc656d42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings from animal studies and its mechanism of action, IWILFIN can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of eflornithine to pregnant rats and rabbits during the period of organogenesis resulted in embryolethality at doses equivalent to the recommended human dose.</paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="5b429445-a081-4bb7-aae3-8864b442f537"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6	ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Myelosuppression <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hearing Loss <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Most common adverse reactions (incidence ≥5%) are hearing loss, otitis media, pyrexia, pneumonia, and diarrhea. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>Most common Grade 3 or 4 laboratory abnormalities (incidence ≥2%) are increased ALT, increased AST, decreased neutrophil count, and decreased hemoglobin. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact US WorldMeds at 1-877-IWILFIN or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="4283526d-5afd-4031-8f71-09b675187229"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in clinical practice.</paragraph>
                        <paragraph>The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to IWILFIN as a single agent, taken orally at doses ranging from 192 - 768 mg twice daily, based on body surface area (BSA), until disease progression, unacceptable toxicity, or for a maximum of 2 years in patients who demonstrated at least a partial response to prior multiagent, multimodality therapy for newly diagnosed or relapsed/refractory high-risk neuroblastoma in Study 3b (n=101; NCT02395666) and Study 14 (n=259; NCT02679144). Among 360 patients who received IWILFIN, 84% were exposed for 6 months or longer and 73% were exposed for greater than one year. In this pooled safety population, the most common (≥5%) adverse reactions were hearing loss (11%), otitis media (10%), pyrexia (7%), pneumonia (5%), and diarrhea (5%). The most common (≥2%) Grade 3 or 4 laboratory abnormalities were increased ALT (11%), increased AST (6%), decreased neutrophils (4.2%), and decreased hemoglobin (3.3%).</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section>
                           <id root="3d08e05d-a414-46bd-80bb-07707ea90add"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Study 3b</content>
                              </paragraph>
                              <paragraph>The safety of IWILFIN was evaluated in Study 3b <content styleCode="italics">[see Clinical Studies (14.1)]</content>. Eligible patients were pediatric patients with high-risk neuroblastoma (HRNB) who demonstrated at least a partial response to prior multiagent, multimodality therapy including induction, consolidation, and anti-GD2 immunotherapy. Patients received IWILFIN as a single agent taken orally at doses ranging from 192 - 768 mg twice daily, based on body surface area (BSA), until disease progression, unacceptable toxicity, or for a maximum of 2 years (N=85). Among patients who received IWILFIN, 93% were exposed for 6 months or longer and 89% were exposed for greater than one year.</paragraph>
                              <paragraph>The median age of patients who received IWILFIN was 4 years (range: 1 to 17); 59% male; 85% White, 7% Black, 1% Asian, 8% Hispanic or Latino; 87% had International Neuroblastoma Staging System Stage 4 disease; 47% had neuroblastoma with known MYCN-amplification.</paragraph>
                              <paragraph>Serious adverse reactions occurred in 12% of patients who received IWILFIN. Serious adverse reactions in &gt;1 patient included skin infection (3 patients).</paragraph>
                              <paragraph>Permanent discontinuation of IWILFIN due to an adverse reaction occurred in 11% of patients. Adverse reactions which resulted in permanent discontinuation of IWILFIN in &gt;1 patient included hearing loss.</paragraph>
                              <paragraph>Dose reductions of IWILFIN due to an adverse reaction occurred in 8% of patients. Adverse reactions which required dose reductions in &gt;1 patient included hearing loss.</paragraph>
                              <paragraph>The most common (≥5%) adverse reactions, including laboratory abnormalities, were otitis media, diarrhea, cough, sinusitis, pneumonia, upper respiratory tract infection, conjunctivitis, vomiting, pyrexia, allergic rhinitis, decreased neutrophils, increased ALT, increased AST, hearing loss, skin infection, and urinary tract infection.</paragraph>
                              <paragraph>Table 5 summarizes the adverse reactions in Study 3b.</paragraph>
                              <table width="70%">
                                 <caption>Table 5: Adverse Reactions (≥5%) in Patients with HRNB Who Received IWILFIN in Study 3b</caption>
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" rowspan="2">Adverse Reaction<footnote ID="t4ft1">Severity as defined by CTCAE Version 4.03.</footnote>
                                       </th>
                                       <th styleCode="Rrule Botrule" colspan="2">IWILFIN<br/>(n=85)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">All Grades<footnote ID="t4ft2">Grade 1 adverse events were not comprehensively collected in Study 3b.</footnote>
                                          <sup>,</sup>
                                          <footnote ID="t4ft3">No Grade 4 or 5 events were reported.</footnote>
                                          <br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Infections</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Otitis media</td>
                                       <td styleCode="Rrule">32</td>
                                       <td styleCode="Rrule">2.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sinusitis</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pneumonia</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Upper respiratory tract infection</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Conjunctivitis </td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Skin infection</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">4.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Urinary tract infection</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">1.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea<footnote ID="t4ft4">Includes colitis.</footnote>
                                       </td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Respiratory Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Allergic rhinitis</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">General Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pyrexia</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Ear and Labyrinth Disorders</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Hearing loss</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Clinically relevant adverse reactions in &lt;5% of patients who received IWILFIN included rash, extremity pain, and alopecia.</paragraph>
                              <paragraph>Table 6 summarizes the laboratory abnormalities in Study 3b.</paragraph>
                              <table width="70%">
                                 <caption>Table 6:	Select Laboratory Abnormalities (≥1%) in Patients with HRNB Who Received IWILFIN in Study 3b</caption>
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" rowspan="2">Laboratory Abnormality<footnote ID="t5ft1">Severity as defined by CTCAE Version 4.03.</footnote>
                                       </th>
                                       <th styleCode="Rrule Botrule" colspan="2">IWILFIN<br/>(n=85)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">All Grades<footnote ID="t5ft2">Grade 1 adverse events were not comprehensively collected in Study 3b.</footnote>
                                          <sup>,</sup>
                                          <footnote ID="t5ft3">No Grade 5 events occurred.</footnote>
                                          <br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Chemistry</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased ALT</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">7<footnote ID="t5ft4">No Grade 4 events occurred.</footnote>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased AST</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">6<footnoteRef IDREF="t5ft4"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased alkaline phosphatase</td>
                                       <td styleCode="Rrule">4.7</td>
                                       <td styleCode="Rrule">2.4<footnoteRef IDREF="t5ft4"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased potassium</td>
                                       <td styleCode="Rrule">2.4</td>
                                       <td styleCode="Rrule">2.4<footnoteRef IDREF="t5ft4"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased glucose</td>
                                       <td styleCode="Rrule">2.4</td>
                                       <td styleCode="Rrule">1.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased sodium</td>
                                       <td styleCode="Rrule">2.4</td>
                                       <td styleCode="Rrule">2.4<footnoteRef IDREF="t5ft4"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased potassium</td>
                                       <td styleCode="Rrule">1.2</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased glucose</td>
                                       <td styleCode="Rrule">1.2</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Hematology</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased neutrophils</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased hemoglobin</td>
                                       <td styleCode="Rrule">4.7</td>
                                       <td styleCode="Rrule">2.4<footnoteRef IDREF="t5ft4"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased white blood cells</td>
                                       <td styleCode="Rrule">2.4</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Decreased platelets</td>
                                       <td styleCode="Rrule">1.2</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="151a951c-6ea3-4c0d-be19-d0d2d7a78690"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</paragraph>
                        <paragraph>Renal Impairment: Reduce the dose in patients with estimated Glomerular Filtration Rate (eGFR) &lt;30 mL/min. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S8.5">8.5</linkHtml>, <linkHtml href="#S12.3">12.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="02de6f95-aafa-4b60-8f8f-92735f6be4c7"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy</title>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section>
                           <id root="e6356ae5-cc71-4180-88a3-42038cdd1fff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on findings from animal studies and its mechanism of action <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>
                                 </content>], IWILFIN can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of eflornithine to pregnant rats and rabbits during the period of organogenesis resulted in embryolethality at doses equivalent to the recommended human dose <content styleCode="italics">[see <linkHtml href="#data">Data</linkHtml>]</content>. There are no available data on the use of IWILFIN in pregnant women. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="278313b0-b698-4561-92a3-bd71e7ede1af"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                           <component>
                              <section>
                                 <id root="6068102b-26e5-4a85-929a-4a038321e6bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study, once daily oral administration of 30, 80 or 200 mg/kg/day eflornithine to pregnant rats during the period of organogenesis (gestation day 6 to 7) resulted in reduced fetal body weights and an increase in the incidence of skeletal variations (presence of a 14th rudimentary rib, 14th full rib, 27th presacral vertebrae) at 200 mg/kg/day [approximately 0.8 to 2 times the recommended human dose of 1152 ± 384 mg/m<sup>2</sup>/day based on body surface area (BSA)]. In a dose range-finding embryo-fetal development study, pregnant rats receiving oral administration of up to 2000 mg/kg/day eflornithine during the period of organogenesis exhibited increased early resorptions and post-implantation loss beginning at 300 mg/kg/day (approximately 1 to 2 times the recommended human dose of 1152 ± 384 mg/m<sup>2</sup>/day based on BSA), with 100% post-implantation loss and no viable fetuses at ≥800 mg/kg/day (approximately ≥3 to 6  times the recommended human dose of 1152 ± 384 mg/m<sup>2</sup>/day based on BSA).</paragraph>
                                    <paragraph>In an embryo-fetal development study in rabbits, once daily oral administration of 15, 45 or 135 mg/kg/day eflornithine to pregnant animals during the period of organogenesis (gestation day 7 to 20) resulted in reduced gravid uterine weight accompanied by increased pre-implantation and post-implantation loss, increased early resorptions, and reduced fetal body weights at 135 mg/kg/day (approximately 1 to 2 times the recommended human dose of 1152 ± 384 mg/m<sup>2</sup>/day based on BSA). Eflornithine resulted in abortions in one animal at 15 mg/kg/day (approximately 0.1 to 0.2 times the recommended human dose of 1152 ± 384 mg/m<sup>2</sup>/day based on BSA) and one animal at 135 mg/kg/day. In a dose range-finding embryo-fetal development study, pregnant rabbits receiving oral administration of up to 500 mg/kg/day eflornithine during the period of organogenesis exhibited 100% post-implantation loss and no viable fetuses at 500 mg/kg/day (approximately 4 to 8 times the recommended human dose of 1152 ± 384 mg/m<sup>2</sup>/day based on BSA). There was no clear evidence of eflornithine-related fetal malformations in rats or rabbits.</paragraph>
                                 </text>
                                 <effectiveTime value="20241130"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="ff0b9fc5-f762-449c-a099-aea7d12e8346"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section>
                           <id root="ef3acca8-6c99-4206-ae57-efc68677cff4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of eflornithine in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with IWILFIN and for 1 week after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="7c1f78b3-7371-4671-a814-bc6ac074596b"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3	Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Based on animal data and its mechanism of action, IWILFIN can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section>
                           <id root="9f453be4-0d71-4a52-8691-cff419d09ca7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating IWILFIN <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="75596a23-4ccd-4493-80e6-756ea74c2853"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                           <component>
                              <section>
                                 <id root="c4740aa8-abb9-416e-a4b3-3bddc7c3f19d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20241130"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="ccbfa8ea-4e96-453e-9544-f73dbf81f341"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20241130"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="18886a50-bd9c-4b5a-8502-6ed817734df0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of IWILFIN have been established to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. Use of IWILFIN for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients with a median age of 4 years (range: 1 to 17) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, Clinical Studies (14.1)].</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of IWILFIN have not been established in pediatric patients for other indications <content styleCode="italics">[see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="7adb5ef9-3393-43ce-bad6-89e7508208ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Renal Impairment</title>
                     <text>
                        <paragraph>Patients with moderate (eGFR &lt;60 mL/min) and severe (eGFR &lt;30 mL/min) renal impairment have a higher exposure to eflornithine than patients with normal renal function which can increase the risk for toxicity <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content> Reduce the dose in patients with severe renal impairment <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>. Monitor patients with moderate renal impairment closely for increased adverse reactions including hepatotoxicity, myelosuppression, and hearing loss <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="332f8154-3a10-497f-9831-10cc121cbdca"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11	DESCRIPTION</title>
               <text>
                  <paragraph>IWILFIN is an ornithine decarboxylase inhibitor. The chemical name of eflornithine hydrochloride is 2,5-diamino-2-(difluoromethyl) pentanoic acid hydrochloride hydrate with a molecular formula of C<sub>6</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>∙HCl∙H<sub>2</sub>O. Its molecular weight is 236.65g/mol for the salt and hydrate form and 182.17 g/mol for the anhydrous free base form. Eflornithine hydrochloride is a white to off-white powder, freely soluble in water and sparingly soluble in ethanol. The chemical structure of eflornithine hydrochloride is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>IWILFIN is available as a round, white to off-white tablet for oral administration. Each tablet contains 192 mg eflornithine, equivalent to 250 mg of eflornithine hydrochloride, and the following inactive ingredients: 220 mg silicified microcrystalline cellulose, 25 mg partially pregelatinized maize starch, 2.5 mg colloidal silicon dioxide, and 2.5 mg vegetable source magnesium stearate.</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="iwilfin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="b81c04d6-b76f-4148-865e-0c433c4d0a37"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241130"/>
               <component>
                  <section ID="S12.1">
                     <id root="f77e7364-0b86-463b-9038-f1651634319f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Eflornithine is an irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines and a transcriptional target of <content styleCode="italics">MYCN</content>. Polyamines are involved in differentiation and proliferation of mammalian cells and are important for neoplastic transformation. Inhibition of polyamine synthesis by eflornithine restored the balance of the LIN28/Let-7 metabolic pathway, which is involved in regulation of cancer stem cells and glycolytic metabolism, by decreasing expression of the oncogenic drivers MYCN and LIN28B in <content styleCode="italics">MYCN</content>-amplified neuroblastoma. In vitro, eflornithine induced senescence and suppressed neurosphere formation in <content styleCode="italics">MYCN</content>-amplified and <content styleCode="italics">MYCN</content> non-amplified neuroblastoma cells, indicating a cytostatic effect. Treatment with eflornithine prevented or delayed tumor formation in mice injected with limiting dilutions of <content styleCode="italics">MYCN</content>-amplified neuroblastoma cells.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="f03488e8-df81-487d-9544-43459c2da93d"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2	Pharmacodynamics</title>
                     <text>
                        <paragraph>Eflornithine exposure-response relationships and the time course of pharmacodynamic responses are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section>
                           <id root="ac7a4481-6096-4d54-8766-b66898ce485f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At the recommended dose, IWILFIN did not result in a large mean increase (i.e., &gt;20 ms) of the QTc interval.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="1485831f-0fa2-4ea5-8f5f-fef98b93b910"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	Pharmacokinetics</title>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section>
                           <id root="51433752-d86f-42e1-8c9d-4ce6e80e66a8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following oral administrations of IWILFIN, peak plasma concentrations of eflornithine (C<sub>max</sub>) were achieved (T<sub>max</sub>) 3.5 hours post dosing. </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                           <component>
                              <section>
                                 <id root="9441386a-bb97-4046-b87f-2cd42273f93e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>The C<sub>max</sub> and AUC (area under the concentration-time curve) of eflornithine were not affected by food (high fat and high calories). Administration of crushed tablets in a standard pudding admixture had no effect on eflornithine exposure (C<sub>max</sub> and AUC<sub>6h</sub>).  </paragraph>
                                 </text>
                                 <effectiveTime value="20241130"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="09799678-c58d-4f1a-8d48-4285a35438f5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Eflornithine does not specifically bind to human plasma proteins. Eflornithine volume of distribution (Vz/F) is 24.3 L.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="08a18d38-ab20-4a3f-9641-32f301ca9fbe"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                           <component>
                              <section>
                                 <id root="a06fdbc9-2962-4a58-901a-324f1618e1de"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Terminal plasma elimination half-life of eflornithine is 3.5 hours. Clearance (CL/F) is 5.3 L/h. </paragraph>
                                 </text>
                                 <effectiveTime value="20241130"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="018fc7c0-a60f-46f3-b28a-f79b4d540663"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>Pharmacokinetic analyses from patients in Study 14 suggested that age (1 year to 19 years), sex, or body surface area (0.4 m<sup>2</sup> to 2 m<sup>2</sup>), and mild hepatic impairment (bilirubin ≤ULN and AST&gt;ULN or bilirubin &gt;1 × ULN and any AST) had no clinically meaningful effects on eflornithine exposure.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                           <component>
                              <section>
                                 <id root="8ec8a1d7-1590-4557-8f8f-c56aac4b8fde"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Following oral administration of a single IWILFIN dose of 576 mg, exposure (AUC) of eflornithine was 2-fold higher in adults with moderate renal impairment and 4-fold higher in adults with severe renal impairment when compared to adults with normal renal function.</paragraph>
                                 </text>
                                 <effectiveTime value="20241130"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="ab2682e2-b5b0-4273-aea0-5a2d80cebd1b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241130"/>
               <component>
                  <section ID="S13.1">
                     <id root="290d6ba6-84cc-4ce7-8d2d-6f63a7a5500d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>In a 2-year carcinogenicity study, once daily oral administration of eflornithine to female rats did not result in drug-related neoplasms at doses up to 600 mg/kg/day (10.5 times the human C<sub>max</sub> at the recommended clinical dose of 1152 ± 384 mg/m<sup>2</sup>).</paragraph>
                        <paragraph>Eflornithine was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay.</paragraph>
                        <paragraph>Dedicated fertility studies were not conducted with eflornithine.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="98585b6d-b225-437e-b397-61519a145dde"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of IWILFIN is based on an externally controlled trial comparison of Study 3b (investigational arm) and Study ANBL0032 (clinical trial-derived external control arm).</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <section>
                     <id root="e9235014-6229-4a50-b4f6-20b28407ef04"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Study 3b</content>
                        </paragraph>
                        <paragraph>Study 3b (NCT02395666) was a multi-center, open label, non-randomized trial with two cohorts. Eligible patients in one cohort (Stratum 1) were pediatric patients with high-risk neuroblastoma (HRNB) who demonstrated at least a partial response to prior multiagent, multimodality therapy, including induction, consolidation, and anti-GD2 immunotherapy. A total of 105 eligible patients received IWILFIN orally twice daily, dosage based on body surface area (BSA) until disease progression, unacceptable toxicity, or for a maximum of 2 years <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content> Tumor assessments were performed at 3, 6, 9, 12, 18 months, completion of treatment, and as clinically indicated. Following completion of IWILFIN therapy, patients were followed for a total duration of 7 years. The major efficacy outcome measure was event free survival (EFS), defined as disease progression, relapse, secondary cancer, or death due to any cause. An additional efficacy outcome measure was overall survival (OS), defined as death due to any cause. Study 3b was prospectively designed to compare outcomes to the historical EFS rate from Study ANBL0032 reported in published literature. </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="17e1f8cf-f0c2-4774-9c46-75078a90e912"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">External Comparator: ANBL0032</content>
                        </paragraph>
                        <paragraph>The external control arm was derived from 1,241 patients on the experimental arm of Study ANBL0032, a multi-center, open-label, randomized trial of dinutuximab, granulocyte-macrophage colony-stimulating factor, interleukin-2, and cis-retinoic acid compared to cis-retinoic acid alone in pediatric patients with HRNB previously treated with induction and consolidation therapy who achieved at least a partial response to prior autologous stem cell transplant. Tumor assessments were performed post-immunotherapy at 3, 6, 9, 12, 18, 24, 30, and 36 months, then per standard of care for a total of 10 years. </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8b465a7d-ae04-4d2e-a624-9cd7bc8220f6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Externally Controlled Trial</content>
                        </paragraph>
                        <paragraph>The efficacy population for the comparative analysis of Study 3b and ANBL0032 included patients from both studies who were less than 21 years of age with histologic verification of HRNB and who demonstrated at least a partial response based on imaging, with no evidence of disease in the bone marrow, at the end of immunotherapy, and did not experience an EFS event prior to starting IWILFIN maintenance therapy (for Study 3b), or for at least 30 days from the end of immunotherapy (for ANBL0032). Eligible patients on Study 3b received immunotherapy on ANBL0032 or were treated off study according to the ANBL0032 protocol. Patients who met the criteria for the comparison and had complete data for specified clinical covariates were matched (1:3) using propensity scores; the matched efficacy populations for the primary analysis included 90 patients treated with IWILFIN and 270 control patients from ANBL0032. The demographic characteristics of the primary analysis population (N=360) were 59% male; median age at diagnosis 3 years (range: 0.1 to 20.1); 88% White, 6% Black, 4% Asian, 7% Hispanic. The majority of patients had Stage 4 disease (86%) and MYCN amplification was observed in 44% of tumors. End of immunotherapy responses were complete response (CR; 87%), very good partial response (VGPR; 8%), or partial response (PR; 5%).</paragraph>
                        <paragraph>In the protocol-specified primary analysis, the EFS hazard ratio (HR) was 0.48 (95% CI: 0.27, 0.85) and OS HR was 0.32 (95% CI: 0.15, 0.70). The Kaplan-Meier plot for the primary analysis of EFS, with shaded bands for each curve representing the point-wise 95% confidence intervals, is shown in Figure 1. Given the uncertainty associated with the externally controlled study design, supplementary analyses in subpopulations or using alternative statistical methods were performed. In these analyses, the EFS HR ranged from 0.43 (95% CI: 0.23, 0.79) to 0.59 (95% CI: 0.28, 1.27), and the OS HR ranged from 0.29 (95% CI: 0.11, 0.72) to 0.45 (95% CI: 0.21, 0.98).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1: Kaplan-Meier Curve for Event Free Survival for Protocol-Specified Primary Analysis in the Externally Controlled Trial</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM2"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="iwilfin-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="47c2b22f-cfb6-4497-92a0-5d1439b2d2ad"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>IWILFIN (eflornithine) is available as 192 mg round, white to off-white tablets imprinted with EFL on one side and 192 on the other side; approximately 11 mm in diameter and supplied as follows:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Bottle of 100 tablets containing desiccant, NDC 78670-150-01</item>
                  </list>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <section>
                     <id root="33ad7558-369e-4e49-8e79-0c0fcc88fc91"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at room temperature, 20°C to 25°C (68°F to77°F), excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="44910bba-6149-4bfa-8187-c54c81d70070"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17	PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <section>
                     <id root="50ee15a6-0411-4540-8868-c802e2efc0e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Myelosuppression</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers of the risk of bone marrow suppression and to promptly report any signs or symptoms of thrombocytopenia, anemia, or infection <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4831c484-6578-4228-8f9f-e0890a4f9019"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers of the risk of hepatotoxicity and to promptly report any signs or symptoms of hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3dc2a515-8ec3-44af-92b8-f9962112fb71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hearing Loss</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers of the risk of hearing loss, and to promptly report any signs or symptoms of new or worsening hearing loss <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="37918c8d-ed0f-4649-812a-db869443706d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryofetal Toxicity</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers that IWILFIN can be harmful to a developing fetus and cause loss of pregnancy <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>. Advise females of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b986b0dc-124f-4396-a8cb-863e2e4a2e64"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with IWILFIN and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="0bd08a23-d3a7-42a7-a9c9-fb08513d4b4a"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>US WorldMeds<sup>®</sup>
                  </paragraph>
                  <paragraph>Distributed by:<br/>USWM, LLC<br/>4441 Springdale Road<br/>Louisville, KY 40241</paragraph>
                  <paragraph>©2025. IWILFIN® is a registered trademark of USWM, LLC.</paragraph>
                  <paragraph>FPI-0026.1</paragraph>
               </text>
               <effectiveTime value="20241130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="51dbacc7-01bb-4fba-928a-f6806e62eed9"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <col width="47%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td align="left" valign="top" colspan="2">This Patient Information has been approved by the U.S. Food and Drug Administration</td>
                           <td align="right" valign="top">Issued: 12/2023</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="center">
                              <content styleCode="bold">Patient Information<br/>IWILFIN<sup>®</sup>
                              </content> (I-WILL-fin)<br/>
                              <content styleCode="bold">(eflornithine)</content>
                              <br/>tablets</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is IWILFIN?</content>
                              <br/>IWILFIN is a prescription medicine used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB) who have had at least a partial response to certain prior therapies.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Before you take IWILFIN, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have hearing problems</item>
                                 <item>are pregnant or plan to become pregnant. IWILFIN can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with IWILFIN or think you may be pregnant.<list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Females</content> who are able to become pregnant should have a pregnancy test before starting treatment with IWILFIN.<br/>You should use effective birth control during treatment with IWILFIN and for 1 week after the last dose.</item>
                                       <item>
                                          <content styleCode="bold">Males</content> who have female partners who are able to become pregnant should use effective birth control during treatment with IWILFIN and for 1 week after the last dose.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if IWILFIN passes into your breast milk. Do not breastfeed during treatment with IWILFIN and for 1 week after the last dose.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take IWILFIN?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take IWILFIN exactly as your healthcare provider tells you to take it.</item>
                                 <item>Take IWILFIN 2 times a day with or without food.</item>
                                 <item>Swallow tablets whole. If you cannot swallow tablets whole, IWILFIN can be chewed, or crushed then mixed with soft food or liquid. If you are crushing IWILFIN tablets:<list listType="unordered" styleCode="circle">
                                       <item>IWILFIN can be crushed then mixed with 2 tablespoons of soft food or liquid.</item>
                                       <item>Eat the entire mixture.</item>
                                       <item>If any crushed tablet pieces remain, mix with another small amount (about 2 tablespoons) of soft food or liquid.</item>
                                       <item>Take all of the mixture within 1 hour of mixing. Throw away any mixture left after 1 hour.</item>
                                    </list>
                                 </item>
                                 <item>If you miss a dose of IWILFIN, take it as soon as you remember. If it is within 7 hours of your next scheduled dose, skip the missed dose and take your next dose at your regular time.</item>
                                 <item>If you vomit after taking a dose, do not take an extra dose. Take your next dose at your regular time.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of IWILFIN?<br/>IWILFIN may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Low blood cell counts</content>. IWILFIN can cause low blood cell counts and failure of your bone marrow to make enough platelets, red blood cells, or white blood cells. Your healthcare provider will monitor your blood cell counts before starting and during treatment with IWILFIN. Tell your healthcare provider right away if you develop symptoms of low blood cell counts, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>fever (temperature 100.4°F or higher)</item>
                                 <item>easy bruising or bleeding</item>
                                 <item>blood in your urine or stools</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>feeling unusually tired or weak</item>
                                 <item>shortness of breath</item>
                                 <item>chills or shivering</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Liver problems.</content> Your healthcare provider will do blood tests before starting, every month for the first 6 months, and regularly during treatment with IWILFIN to check your liver. Tell your healthcare provider if you develop symptoms of liver problems, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>your skin or the white part of your eyes turns yellow (jaundice)</item>
                                 <item>dark or "tea-colored" urine</item>
                                 <item>light-colored stools (bowel movements)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>nausea or vomiting</item>
                                 <item>easy bruising or bleeding</item>
                                 <item>loss of appetite</item>
                                 <item>pain, aching, or tenderness on the right side of your stomach-area (abdomen)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">New or worsening hearing loss.</content> Hearing loss is common during treatment with IWILFIN and can also be serious. Your healthcare provider will check your hearing before you start and during treatment with IWILFIN. Some people have needed to use hearing aids. Tell your healthcare provider right way if you get ringing in your ears or any new or worsening hearing loss.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of IWILFIN include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>ear infection</item>
                                 <item>diarrhea</item>
                                 <item>cough</item>
                                 <item>sinus infection</item>
                                 <item>pneumonia</item>
                                 <item>upper respiratory tract infection</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>red and swollen eyes (pink eye)</item>
                                 <item>vomiting</item>
                                 <item>stuffy, runny, itchy nose or sneezing (allergic rhinitis)</item>
                                 <item>fever</item>
                                 <item>skin infection</item>
                                 <item>urinary tract infection</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">These are not all the possible side effects of IWILFIN.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store IWILFIN?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store IWILFIN at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                              </list>
                              <content styleCode="bold">Keep IWILFIN and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of IWILFIN:</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use IWILFIN for a condition for which it was not prescribed. Do not give IWILFIN to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about IWILFIN that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in IWILFIN?<br/>Active ingredient:</content> eflornithine<br/>
                              <content styleCode="bold">Inactive ingredients:</content> silicified microcrystalline cellulose, partially pregelatinized maize starch, colloidal silicon dioxide, and vegetable source magnesium stearate.<br/>Distributed by:<br/>USWM, LLC 4441 Springdale Road Louisville, KY 40241<br/>©2025. IWILFIN® is a registered trademark of USWM, LLC.<br/>For more information, go to www.IWILFIN.com or call 1-877-IWILFIN.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="c7157a1b-dd56-4c7d-91a0-1389d81430fb"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 192 mg Bottle Carton</title>
               <text>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 78670-150-01</paragraph>
                  <paragraph>iwilfin™<br/>(eflornithine) tablets</paragraph>
                  <paragraph>192 mg</paragraph>
                  <paragraph>Keep the bottle tightly closed.</paragraph>
                  <paragraph>100 tablets</paragraph>
                  <paragraph>US WorldMeds<sup>®</sup>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 192 mg Bottle Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="iwilfin-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>